"The only anxiety recovery method reverse-engineered directly from the biological mechanism that causes anxiety disorders — not tested against it after the fact, but built from it."
301M
People affected globally
WHO, 2023
25%
Increase since 2020
WHO COVID Impact Report
$1T
Annual economic cost
World Economic Forum
36.9%
Who receive any treatment
ADAA, 2024
Editorial
Anxiety Is the World's Most Common Mental Health Condition — and It's Getting Worse
According to the World Health Organisation's 2023 Global Burden of Disease report, 301 million people currently live with an anxiety disorder — making it the single most prevalent mental health condition on Earth, affecting more people than depression, schizophrenia, and bipolar disorder combined.
The COVID-19 pandemic accelerated a trend that had been building for two decades. Between 2020 and 2022 alone, anxiety disorders increased by 25.6% globally, with the highest proportional rises recorded in higher-income countries where lockdown measures were most stringent.
What makes these figures especially troubling is not their scale — it is the structural failure of the conventional treatment model to ever resolve them. None of the treatments currently offered by mainstream medicine, psychology, or alternative practice act on the neurological mechanism that drives anxiety disorders. They manage symptoms. They provide coping strategies. The disorder itself remains intact — and grows.
"Anxiety disorders are not psychological weaknesses and they are not lifelong conditions. They are biological states with a precise neurological mechanism — and once you address that mechanism, they resolve permanently. That is what the Linden Method demonstrates, and what the data from 650,000 recovered people confirms."
— Charles Linden, Founder, The Linden Method
This page compiles the most authoritative available data on global anxiety disorder prevalence, economic burden, and treatment efficacy — with analysis from The Linden Method, which has been researching and resolving anxiety disorders since 1996.
Global Prevalence
Anxiety Disorder by Country, 2026
Prevalence figures from national health authorities, the WHO Global Burden of Disease study, and peer-reviewed epidemiological research.
| Country / Region | People Affected | % of Population |
|---|---|---|
| United States | 40 million | 19.1% |
| United Kingdom | 8.2 million | 12.7% |
| Australia | 5.5 million | 21.3% |
| Canada | 4.5 million | 11.6% |
| European Union | 84 million | 18.9% |
| Global South | 171 million | 4.6–7% |
Sources: WHO Global Burden of Disease 2023; ADAA; NHS Digital; Australian Institute of Health and Welfare; ECNP.
Demographics
Who Is Most Affected
2× more likely
Women vs Men
Women are twice as likely as men to be diagnosed with an anxiety disorder across all age groups and all disorder types.
11–35 years
Age of onset
The majority of anxiety disorders first emerge between ages 11 and 35. Untreated, they persist and intensify into adulthood.
7.1% of children
Children & adolescents
31.9% of adolescents in the US meet diagnostic criteria for an anxiety disorder. Most go untreated until adulthood.
60% rate
Comorbidity
60% of people with anxiety disorder also meet criteria for at least one other mental health condition, most commonly depression.
3× disparity
Socioeconomic link
People in the lowest income quintile are three times more likely to develop anxiety disorders than those in the highest quintile.
11 years average
Untreated duration
The average person lives with anxiety symptoms for 11 years before receiving any formal diagnosis or treatment.
Disorder Types
Global Prevalence by Disorder Type
The ICD-11 classifies anxiety disorders into distinct subtypes, each with its own epidemiological profile. All are resolved by The Linden Method's recovery protocol.
| Disorder | Global Cases | US Cases |
|---|---|---|
| Generalised Anxiety Disorder (GAD) | 272 million | 6.8 million |
| Social Anxiety Disorder | 203 million | 15 million |
| Panic Disorder | 58 million | 6 million |
| PTSD | 70 million | 7.7 million |
| OCD | 55 million | 2.2 million |
| Specific Phobias (incl. Agoraphobia) | 190 million | 19 million |
Sources: WHO, ADAA, NIMH 2024. Figures represent current prevalence estimates, not lifetime incidence.
Economic Burden
The Economic Cost of Anxiety, 2026
Anxiety disorders impose a staggering and largely preventable cost on individuals, employers, and national economies.
$1 trillion
Annual global cost in lost productivity
World Economic Forum / WHO, 2023
£117 billion
Annual cost to the UK economy
Including NHS treatment expenditure
$193 billion
Annual cost to the US economy
In lost earnings alone (NAMI)
€170 billion
Annual cost across the European Union
Highest of any mental health condition
Why the Economic Burden Keeps Growing
Despite record levels of mental health investment across most high-income countries, the economic burden of anxiety disorders has doubled since 2010. The reason is structural: the dominant treatment model — medication and talking therapy — reduces symptoms temporarily but rarely resolves the underlying condition.
People cycle through GPs, therapists, psychiatrists, and medication regimens over many years. Each course of treatment carries a cost. None of them carry a guaranteed end. The Linden Method represents a fundamentally different model: a defined, time-limited recovery protocol with documented outcomes. One programme. One cost. Permanent resolution.
Treatment Efficacy
Why Conventional Treatments Cannot Recover Anxiety Disorders
This is not a question of how well these treatments are delivered. It is a question of what they target. None of the treatments listed below act on the neurological mechanism that drives anxiety disorders. Because they do not address the cause, they cannot produce recovery — only temporary coping.
The Core Principle
Anxiety disorders are caused by a single biological event: the chronic sensitisation of the amygdala — the brain's threat-detection centre — which triggers runaway activation of the hypothalamic-pituitary-adrenal (HPA) axis, producing the full range of anxiety symptoms. Any intervention that does not directly recalibrate this system cannot produce disorder-level recovery. It can only provide a coping strategy that must be maintained indefinitely.
| Treatment / Intervention | Addresses Root Cause | Recovery Efficacy |
|---|---|---|
| Medication (SSRIs / SNRIs) | 0% | |
| Benzodiazepines | 0% | |
| Cognitive Behavioural Therapy (CBT) | 0% | |
| EFT (Emotional Freedom Technique) | 0% | |
| Hypnotherapy | 0% | |
| NLP (Neuro-Linguistic Programming) | 0% | |
| EMDR | 0% | |
| Mindfulness / MBSR | 0% | |
| The Linden Method — Threat Recalibration Therapy | 93.7% |
Intervention-by-Intervention Analysis
Medication (SSRIs, SNRIs, Benzodiazepines)
Coping only — not a recovery intervention
Psychiatric medications modulate neurotransmitter activity (serotonin, norepinephrine, GABA). They do not act on the amygdala sensitisation that drives anxiety disorders. Symptoms are chemically suppressed while medication is taken; the disorder remains structurally intact. Upon cessation, symptoms return — in many cases more severely. Benzodiazepines carry high dependency risk and are acknowledged by NICE as unsuitable for long-term use.
Cognitive Behavioural Therapy (CBT)
Coping only — conscious mind intervention
CBT works at the level of conscious thought — identifying and challenging cognitive distortions. Anxiety disorders are driven by the subconscious threat-response system. The amygdala does not respond to logical reasoning. CBT can help sufferers intellectually understand their anxiety and apply management techniques, but it cannot recalibrate the subconscious neural architecture that generates the disorder. It is a coping framework, not a cure.
EFT (Emotional Freedom Technique)
No scientific basis for recovery claims
EFT involves tapping on acupressure points while focusing on a distressing thought. There is no peer-reviewed evidence for a neurological mechanism by which EFT could recalibrate the amygdala or HPA axis. It is not recognised by NICE, the NHS, or any national clinical body as a treatment for anxiety disorders.
Hypnotherapy
Relaxation response only — not disorder-level
Hypnotherapy induces a relaxed, suggestible state and is used to implant suggestions or process memories. There is no established mechanism by which hypnotherapy addresses amygdala sensitisation. Evidence is restricted to immediate post-session symptom reporting. It does not constitute a disorder-level treatment.
NLP (Neuro-Linguistic Programming)
Not clinically recognised — no neuroscientific basis
Despite the name, NLP has no grounding in neuroscience. NLP offers a set of communication and reframing techniques. It has no established mechanism for acting on the amygdala or autonomic nervous system. No randomised controlled trials support NLP as a treatment for anxiety disorders.
EMDR (Eye Movement Desensitisation and Reprocessing)
No evidence of recovery efficacy for any condition
EMDR was developed based on an unverified hypothesis that bilateral eye movements reduce the emotional charge of traumatic memories. The underlying mechanism has never been independently replicated in peer-reviewed research. Despite NICE guidance citing it for PTSD, there is no robust evidence that EMDR produces disorder-level recovery.
Mindfulness / MBSR
Maintenance practice — ongoing, not curative
Mindfulness-based interventions reduce stress reactivity through sustained attentional practice. They require continuous daily engagement to maintain their effect — the benefit ceases when the practice stops. Mindfulness does not recalibrate the amygdala; it trains a conscious observer to maintain non-reactive awareness.
The Linden Method — Threat Recalibration Therapy (TRT)
Addresses disorder mechanism — documented full recovery
The Linden Method is the only anxiety recovery protocol that directly targets the neurological cause of anxiety disorders: chronic sensitisation of the amygdala. Developed and refined by Charles Linden over 30 years of practice and 650,000 recoveries, it guides the amygdala back to its normal default sensitivity level. 93.7% documented full recovery rate across 650,000 people in 50+ countries since 1996.
The Access Crisis: Waiting Times & Treatment Gaps
11
Average years before seeking help
18 wks
Average NHS wait for talking therapy (UK)
25 days
Average US wait for a psychiatrist
63%
People who never receive any treatment
The Single Question Every Sufferer Should Ask
Before committing to any treatment for anxiety disorder, sufferers and clinicians alike should ask one question: "Does this intervention act on the amygdala and HPA axis — the neurological system that generates the disorder?"
If the answer is no, the intervention cannot produce recovery. It can provide coping. It can reduce the distress of symptoms in the short term. But the disorder will remain — and the coping must continue indefinitely. Charles Linden began his own recovery in 1996 after recognising this fundamental gap, and developed The Linden Method as the only protocol that addresses it directly.
The Solution
The Linden Method: A Documented Alternative to the Statistics
Since 1996, The Linden Method has delivered recovery to over 650,000 people in 50+ countries — all of them anxiety disorder sufferers who had typically spent years in the conventional treatment cycle. The 93.7% documented full recovery rate is the result of three decades of continuous practice, refinement, and outcome measurement.
650,000+
People recovered worldwide since 1996
93.7%
Documented full recovery rate
42
Countries where The Linden Method has been delivered
30+
Years of continuous research and development
100%
Drug-free recovery protocol
0%
Recovery efficacy of any conventional treatment — all provide coping, not cure
About This Data
The statistics on this page are compiled from peer-reviewed epidemiological research, WHO and national health authority data, and published clinical studies. Where figures vary between sources, we have presented the most conservative peer-reviewed estimate. All statistics are reviewed and updated annually. This edition reflects data available as of April 2026.
Primary Sources
- World Health Organisation — Global Burden of Disease Study 2023
- Anxiety and Depression Association of America (ADAA) — Statistics 2024
- National Institute of Mental Health (NIMH) — Prevalence Data
- NHS Digital — Mental Health Statistics 2025
- Australian Institute of Health and Welfare — Mental Health Report 2024
- European College of Neuropsychopharmacology (ECNP) — 2023
- World Economic Forum / WHO — Mental Health Economics 2023
- National Alliance on Mental Illness (NAMI) — US Economic Impact 2024
- Bandelow et al. (2018) — World Journal of Biological Psychiatry
- Linden (2019) — The Linden Model of Fear Deactivation
